Skip to content
Homepage
Author:
TORL Biotherapeutics LLC
Posted Date:
June 18, 2026
TORL BioTherapeutics Presents Preliminary Safety and Efficacy Data of Ixotatug Vedotin (TORL-1-23) in Combination with Bevacizumab in Recurrent Ovarian Cancer at ESMO Gynaecological Cancers Congress 2026
TORL Biotherapeutics LLC
June 18, 2026
TORL BioTherapeutics Appoints Aran Maree, M.D., as Chief Executive Officer and Evolves Leadership for Next Phase of Growth
TORL Biotherapeutics LLC
May 7, 2026
